Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Inflammatory Carcinoma|Stage IV Breast Inflammatory Carcinoma
Interventions: DRUG: Atezolizumab|DRUG: Cobimetinib|DRUG: Eribulin|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study
Sponsor: M.D. Anderson Cancer Center